The stock price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) has surged by 5.60 when compared to previous closing price of 8.39, but the company has seen a 6.62% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-13 that Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
The stock has a 36-month beta value of 1.15. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DNA is 35.43M, and at present, short sellers hold a 20.68% of that float. On November 13, 2024, the average trading volume of DNA was 1.37M shares.
DNA’s Market Performance
DNA stock saw an increase of 6.62% in the past week, with a monthly gain of 13.74% and a quarterly increase of -13.00%. The volatility ratio for the week is 6.32%, and the volatility levels for the last 30 days are 7.41% for Ginkgo Bioworks Holdings Inc (DNA). The simple moving average for the last 20 days is 6.10% for DNA stock, with a simple moving average of -63.51% for the last 200 days.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at 14.33% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.22% of loss for the given period.
Volatility was left at 7.41%, however, over the last 30 days, the volatility rate increased by 6.32%, as shares surge +1.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.54% upper at present.
During the last 5 trading sessions, DNA rose by +1.02%, which changed the moving average for the period of 200-days by -83.47% in comparison to the 20-day moving average, which settled at $8.33. In addition, Ginkgo Bioworks Holdings Inc saw -86.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $9.09 back on Nov 13 ’24. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $900 using the latest closing price.
Che Austin, the Officer of Ginkgo Bioworks Holdings Inc, proposed sale 99 shares at $8.52 during a trade that took place back on Nov 12 ’24, which means that Che Austin is holding shares at $843 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -2.71 for the present operating margin
- 0.64 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -2.99. The total capital return value is set at -0.43. Equity return is now at value -76.83, with -45.83 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -6358.49.
Currently, EBITDA for the company is -821.29 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 1.54. The receivables turnover for the company is 9.31for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.71.
Conclusion
To sum up, Ginkgo Bioworks Holdings Inc (DNA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
